ASCO 2019: CDK4/6 Inhibitors New Standard of Care for First-Line Tx
MONALEESA-7 results push the practice change needle By Peggy Peck, Editor-in-Chief, BreakingMED...
Read More
Meeting Coverage
ASCO 2019: Researchers Hunt for Breast Cancer Resistance Genes
Pathways that get around PARP inhibitors explored CHICAGO – The cyclin-dependent kinase (CDK) 4/6...
Read More
ASCO 2019: Right to Try Act a Dud?
After a year, just 2 cases reported by FDA CHICAGO —At the one-year mark, the Right to Try Act,...
Read MoreASCO 2019: Adding Clinical Risk to Gene Scoring Predicts Likelihood of Breast Cancer Recurrence
More from TAILORx investigators By Peggy Peck, Editor-in-Chief, BreakingMED CHICAGO — Clinical risk — high versus low risk — integrated into a genomic risk model is prognostic of distant recurrence of breast cancer in women...
Read More
ASCO 2019: Olaparib Finds a Place to Treat Prostate Cancer
DNA repair mechanism damage targeted in advanced disease CHICAGO — Patients diagnosed with...
Read More
ASCO 2019: Men and Women Doctors Report Sexual Harassment
New survey highlights suspected financial impact CHICAGO – Gynecologic oncologists report that...
Read More
ASCO 2019: FDA Launches Project Facilitate to Ease Access to Novel Agents
But the FDA wants to know outcomes for patients taking unapproved drugs CHICAGO — The FDA says it...
Read More
ASCO 2019: New Agent Targets Metastatic Bladder Cancer
Metastatic disease responds to enfortumab vedotin CHICAGO – A new agent that acts as a smart bomb...
Read More
ASCO 2019: Laparoscopy for Liver Mets Equals Open Surgery
Colon cancer spread excised in minimally invasive procedure CHICAGO – In cases where colon cancer...
Read More
ASCO 2019: PARP-Inhibitor Achieves ‘Complete Response’ in Pancreatic Cancer
BRCA was the key to success CHICAGO — Pancreatic cancer trials don’t report complete responses,...
Read More
ASCO 2019: Studies Offer Evidence—ACA Improves Care
Too little, too late to save Obamacare? CHICAGO — As the nation prepares to once again litigate...
Read MoreASCO 2019: Multiple Myeloma Survival Linked to Income and Insurance
Zip code can be a risk factor CHICAGO – Multiple myeloma is a serious and often deadly disease, but outcomes may be better for those whose medical care is covered by private insurers. Or, it’s possible all survival, like...
Read More
ASCO 2019: ENZAMET and TITAN Are Wins in Prostate Cancer
Survival is about more than testosterone suppression CHICAGO — Men with metastatic hormone...
Read More
ASCO 2019: Metformin No Help in Advanced Prostate Cancer
Diabetes drug offers no benefit to non-diabetic patients CHICAGO – Metformin, when added to...
Read More
ASCO 2019: Ribociclib Claims First Ever Overall Survival Benefit for Targeted Therapy. MONALEESA 7 confirms CDK4/6 inhibitor efficacy in younger women
By Peggy Peck, Editor-in-Chief, BreakingMED CHICAGO — Adding the CDK4/6 inhibitor ribociclib to...
Read More
ASCO 2019: Getting on the Same Page with mCODE. ASCO unveils initiative to topple EHR ‘Tower of Babel’
CHICAGO — What if all health systems, all hospitals, and all oncologists spoke the same language —...
Read More
ASCO 2019: Pembrolizumab Changes ‘the Conversation’ in GI Cancer
Immunotherapy drug works as well as chemotherapy in advanced patients CHICAGO – In a...
Read More
Conference Highlights: DDW 2019
New research was presented at DDW 2019, the annual Digestive Disease Week, from May 18-21 in San...
Read More
Conference Highlights: ATS 2019
New research was presented at ATS 2019, The annual American Thoracic Society International...
Read More
ASCO 2019: Diet to Prevent Breast Cancer Death, Precision Medicine, and More
By Peggy Peck, Editor-in-Chief, BreakingMED In advance of the American Society of Clinical...
Read More